Jonathan Riess, MD, MS

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Bayer
    Topic: 
    Advisory Board
    Date added: 
    10/15/2022
    Relationship end date: 
    06/01/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Turning Point
    Topic: 
    Advisory Board
    Date added: 
    10/15/2022
    Relationship end date: 
    02/23/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Daiichi Sankyo
    Topic: 
    Advisory Board
    Date added: 
    10/15/2022
    Relationship end date: 
    02/01/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Beigene
    Topic: 
    Advisory Board
    Date added: 
    10/15/2022
    Relationship end date: 
    03/01/2022

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond